Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Analysts maintain a “Buy” consensus on Rapport Therapeutics, with 10 buy ratings, two strong-buy ratings and one sell rating. The average 12-month price target is $62.86, above the reported share price of $48.67.
• RAPP shares have risen substantially within their 52-week range, trading near $48.67 versus a low of $14.11 and high of $52.93. However, the company reported a quarterly loss of $1.19 per share, missing consensus estimates of a $1.12 loss.
• Institutional investors, including Johnson & Johnson, Algert Global and Walleye Capital, recently initiated positions, while insiders sold 73,034 shares worth approximately $3.48 million over the past quarter.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has earned an average recommendation of "Buy" from the thirteen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $62.8571.

A number of brokerages recently commented on RAPP. Leerink Partners began coverage on Rapport Therapeutics in a research note on Wednesday, June 24th. They set an "outperform" rating and a $52.00 price target for the company. Wall Street Zen downgraded Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. UBS Group reaffirmed a "strong-buy" rating on shares of Rapport Therapeutics in a report on Monday, August 17th. Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Finally, William Blair began coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They issued an "outperform" rating for the company.

Rapport Therapeutics Stock Down 0.2%

Shares of RAPP stock opened at $48.67 on Tuesday. The stock has a market cap of $2.34 billion, a P/E ratio of -16.01 and a beta of 0.97. Rapport Therapeutics has a 52 week low of $14.11 and a 52 week high of $52.93. The company's fifty day simple moving average is $43.61 and its two-hundred day simple moving average is $37.08.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). On average, analysts anticipate that Rapport Therapeutics will post -4.09 EPS for the current fiscal year.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 18,921 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $49.57, for a total transaction of $937,913.97. Following the completion of the transaction, the chief executive officer owned 467,187 shares in the company, valued at $23,158,459.59. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 73,034 shares of company stock worth $3,484,157 over the last quarter. 12.48% of the stock is owned by corporate insiders.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently made changes to their positions in the business. Johnson & Johnson bought a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $74,360,823. Swedbank AB bought a new stake in Rapport Therapeutics during the fourth quarter worth approximately $3,434,000. Algert Global LLC bought a new stake in Rapport Therapeutics during the second quarter worth approximately $9,327,000. Walleye Capital LLC purchased a new stake in Rapport Therapeutics during the second quarter valued at approximately $4,257,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Rapport Therapeutics by 168.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company's stock valued at $7,025,000 after purchasing an additional 141,011 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.